Stockreport

Citizens Lifts Benitec Biopharma Inc. (BNTC) Price Target on Topline Results for Oculopharyngeal Muscular Dystrophy Treatment [Yahoo! Finance]

Benitec Biopharma Inc.  (BNTC) 
US:NASDAQ Investor Relations: benitec.com/for-investors/investor-faqs
PDF raised the stock's price target to $22 from $20 while reiterating an Outperform rating. The price target hike follows topline clinical data results that showed a 100% re [Read more]